STAT December 17, 2025
Adam Feuerstein

Sarepta Therapeutics’ Doug Ingram has taken on unnecessary risks for Duchenne patients

Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025.

He was an easy selection, but unlike some cases in the past, this pick brought me no joy, because the circumstances that earned Ingram this dishonor are tinged with sadness.

In 2024, Ingram moved aggressively,...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech
What’s new with GLP-1s
Navigating the Shift: 2026 Medicare Drug Pricing and the Future of Pharmacy
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model

Share Article